Biktarvy is the most prescribed HIV treatment in the world, but it is not the only option — and for some patients it may not be the best one. Whether you are newly diagnosed and exploring first-line choices, experiencing side effects, facing cost barriers, or simply asking whether a switch makes clinical sense, understanding the available alternatives is a reasonable and important conversation to have with your HIV clinician. SunnyPharma is an independent health education platform; we do not sell or supply medication.
This page compares the main guideline-recommended Biktarvy alternatives, including which are manufactured as licensed generics in India, the key clinical differences between them, and the questions you should ask your clinician before any switch.
This is not switching guidance. Antiretroviral therapy decisions must be made with your HIV clinician. This page provides clinical context to inform that conversation — it does not constitute medical advice and does not replace a consultation with your prescriber.
Why Patients Consider Biktarvy Alternatives
- Cost: Brand Biktarvy carries a US list price of $4,216/month. Patients facing that price often ask their clinician about alternatives — both other branded regimens and, outside the US, licensed generics.
- Side effects: Some patients experience insomnia, vivid dreams, or weight changes on integrase inhibitor-based regimens and explore alternatives.
- Simplification: Patients with strong adherence records sometimes switch to a two-drug regimen such as Dovato to reduce pill burden or long-term drug exposure.
- Comorbidities: Renal impairment, bone density concerns, or cardiovascular risk factors can influence regimen selection.
- Hepatitis B coinfection: Biktarvy is active against HBV due to its emtricitabine and TAF components. Any switch for an HBV-coinfected patient must include agents active against HBV.
- Drug interactions: Biktarvy interacts with antacids, certain supplements, and rifampicin. Patients on complex polypharmacy may need an interaction review.
The Main Biktarvy Alternatives
Dovato is a two-drug regimen (2DR) combining dolutegravir (an integrase inhibitor) and lamivudine (an NRTI). It achieves viral suppression rates comparable to three-drug regimens in treatment-naïve patients with baseline viral loads below 500,000 copies/mL, as demonstrated in the GEMINI-1 and GEMINI-2 phase 3 trials. The two-drug backbone means less long-term drug exposure compared to a three-drug regimen.
Not suitable for: patients with hepatitis B coinfection; patients with HIV RNA ≥500,000 copies/mL at baseline; patients with suspected or confirmed lamivudine or integrase resistance.
Licensed generic dolutegravir/lamivudine is manufactured in India under MPP license.
Triumeq is a three-drug regimen built around dolutegravir with abacavir and lamivudine as the NRTI backbone. Dolutegravir’s resistance barrier is high — comparable to bictegravir.
Important: HLA-B*5701 testing is required before prescribing abacavir. Approximately 5–8% of white patients carry the HLA-B*5701 allele associated with abacavir hypersensitivity syndrome (AHS), which can be severe or fatal. Triumeq may be less preferred in patients with cardiovascular risk factors.
Licensed generic abacavir/dolutegravir/lamivudine is manufactured in India under MPP license.
Symtuza is a protease inhibitor (PI)-based regimen using darunavir boosted by cobicistat. It is generally reserved for situations where integrase inhibitors are not appropriate or preferred — such as patients with documented integrase resistance. Cobicistat has significant drug interaction potential and also affects serum creatinine measurements (a functional effect, not actual renal toxicity).
Generic darunavir and cobicistat-based combinations have more limited availability in India compared to dolutegravir-based options.
Juluca is a two-drug switch regimen indicated for virologically suppressed adults switching from a stable regimen — not for treatment-naïve patients. The SWORD-1 and SWORD-2 trials demonstrated non-inferior viral suppression rates in suppressed patients switching to Juluca.
Restrictions apply: No prior virological failure or resistance to dolutegravir or rilpivirine; no current or anticipated use of proton pump inhibitors; must be taken with a substantial meal (≥500 kcal). Rilpivirine is associated with depression and insomnia in some patients.
Delstrigo is an NNRTI-based three-drug regimen built around doravirine, a newer NNRTI with a favorable resistance profile compared to older agents like efavirenz. It is associated with less CNS toxicity than efavirenz and has a flat effect on lipids. Doravirine has a moderate resistance barrier — lower than dolutegravir or bictegravir.
Delstrigo uses tenofovir disoproxil fumarate (TDF) rather than TAF. TDF should be used with caution in patients with or at risk of renal impairment or low bone mineral density. Generic doravirine-based combinations from India have limited availability.
Side-by-Side Clinical Comparison
| Regimen | Drugs | Class | Resistance Barrier | HBV Active? | Generic in India |
|---|---|---|---|---|---|
| Biktarvy | BIC/FTC/TAF | INSTI + 2 NRTIs | Very high | Yes (FTC + TAF) | Yes |
| Dovato | DTG/3TC | INSTI + NRTI (2DR) | High | No | Yes |
| Triumeq | ABC/DTG/3TC | INSTI + 2 NRTIs | High | Limited | Yes |
| Symtuza | DRV/COBI/FTC/TAF | PI/COBI + 2 NRTIs | High | Yes (FTC + TAF) | Limited |
| Juluca | DTG/RPV | INSTI + NNRTI (2DR) | Moderate–high | No | Limited |
| Delstrigo | DOR/3TC/TDF | NNRTI + 2 NRTIs | Moderate | Limited | Limited |
Which Patients May Benefit From a Switch Away From Biktarvy?
Patients Considering Dovato (DTG/3TC)
Good candidates are virologically suppressed patients with no prior virological failure, no documented integrase or lamivudine resistance, no hepatitis B coinfection, and a desire to reduce overall drug exposure with a two-drug regimen. The TANGO trial demonstrated maintained suppression in patients switching from TDF-based regimens to Dovato.
Patients Considering a Switch for Cost Reasons
If cost is the primary driver, the appropriate first step is the conversation with a clinician about which regimens fit your clinical profile — not the price tag alone. Patients with HBV coinfection cannot use DTG/3TC. Patients with prior lamivudine exposure or documented lamivudine resistance are not suitable for DTG/3TC. US patients facing brand Biktarvy’s list price should first explore the US assistance programs that bring it to $0–$10/month for most people — see our guide to Biktarvy cost without insurance.
Never switch antiretroviral therapy without clinician guidance. Switching between regimens without resistance history review, appropriate monitoring, and medical oversight risks virological failure and development of resistance mutations that may narrow future treatment options permanently.
Licensed Generics Manufactured in India: Market Context
Several of these regimens are manufactured as licensed generics in India under Medicines Patent Pool (MPP) voluntary licensing agreements. These are not counterfeit products — they are produced under license by manufacturers such as Hetero Labs and Cipla, and are widely used in HIV treatment programs across low- and middle-income countries. Reported market prices are provided below for context only.
| Generic | Brand Equivalent | MPP License | Reported India Market Price | Availability |
|---|---|---|---|---|
| B/F/TAF | Biktarvy | Yes (Hetero, Cipla) | ~$150/bottle | Good |
| DTG/3TC | Dovato | Yes (multiple) | ~$60–90/mo | Widely available |
| ABC/DTG/3TC | Triumeq | Yes (multiple) | ~$65–95/mo | Good |
| DRV/COBI/FTC/TAF | Symtuza | Partial | Varies | Limited |
| DTG/RPV | Juluca | Limited | Varies | Limited |
| DOR/3TC/TDF | Delstrigo | Limited | Varies | Limited |
US import note: Generics manufactured in India are not FDA-approved and are not legally importable into the United States for personal use without individual authorization. SunnyPharma is an education platform and does not sell, supply, or facilitate the purchase of any medication. Discuss any treatment decision with your HIV clinician.
Questions to Ask Your HIV Clinician
- Do I have any documented resistance mutations that would limit my options?
- Am I coinfected with hepatitis B? (Eliminates DTG/3TC and other non-HBV-active regimens)
- Have I had my HLA-B*5701 status tested? (Required before any abacavir-containing regimen)
- What is my current eGFR and have I had any renal issues? (Affects TDF vs. TAF preference)
- What is my cardiovascular risk profile? (Relevant for abacavir-containing regimens)
- Are there any current drug interactions I should be aware of with my other medications?
- What US assistance programs could lower what I pay for my current regimen before I consider any change?
Related Pages on SunnyPharma
- Dovato vs Biktarvy: clinical comparison for treatment decisions
- Biktarvy price in India 2026: licensed generic pricing explained
- Biktarvy cost without insurance: every assistance program explained
- Biktarvy side effects: complete clinical data
Frequently Asked Questions
The main guideline-recommended alternatives include Dovato (dolutegravir/lamivudine), Triumeq (abacavir/dolutegravir/lamivudine), Symtuza (darunavir/cobicistat/emtricitabine/TAF), Juluca (dolutegravir/rilpivirine), and Delstrigo (doravirine/lamivudine/TDF). The right choice depends on your resistance history, comorbidities, hepatitis B status, and treatment history.
For appropriate patients, yes. Dovato (dolutegravir/lamivudine) is a guideline-preferred two-drug option for treatment-naïve patients with viral loads below 500,000 copies/mL and no hepatitis B coinfection. Licensed generic DTG/3TC is manufactured in India. It is not suitable for patients with hepatitis B or documented lamivudine resistance.
Both are guideline-recommended three-drug regimens with high-resistance-barrier integrase inhibitors. Biktarvy uses the TAF backbone with better renal and bone safety data. Triumeq requires HLA-B*5701 testing and is less preferred in patients with cardiovascular risk factors. Licensed generic ABC/DTG/3TC is manufactured in India.
Potentially yes, depending on your clinical profile. A switch requires clinician review of your resistance history, HBV status, and a viral load monitoring plan. Licensed generic DTG/3TC is manufactured in India but is not FDA-approved and not legally importable into the US for personal use without authorization. Do not switch antiretroviral therapy without medical supervision.
Reported India market prices are approximately $60–$90/month for generic dolutegravir/lamivudine (Dovato equivalent), $65–$95/month for generic abacavir/dolutegravir/lamivudine (Triumeq equivalent), and around $150 per bottle for generic B/F/TAF (Biktarvy equivalent). These licensed generics are not FDA-approved and not legally importable into the US for personal use without authorization. SunnyPharma does not sell medication.
Yes. Generic dolutegravir and dolutegravir-based combinations including DTG/3TC and ABC/DTG/3TC are manufactured by MPP-licensed Indian manufacturers including Hetero Labs and Cipla. Generic dolutegravir has been available in India longer than generic bictegravir.
Biktarvy itself (B/F/TAF) has favorable renal safety due to TAF’s low plasma exposure. For patients with significant chronic kidney disease, dolutegravir/lamivudine (no nephrotoxic NRTI) may also be appropriate. TDF-containing regimens (Delstrigo) are generally avoided in patients with eGFR below 50 mL/min. Consult your HIV clinician and nephrologist for personalized guidance.
Abacavir-containing regimens (Triumeq) require HLA-B*5701 testing before prescribing. Biktarvy and dolutegravir/lamivudine regimens do not. All patients starting or switching ART should have resistance testing to guide regimen selection.
Yes. All the main alternatives discussed — Dovato, Triumeq, Symtuza, Juluca, and Delstrigo — are once-daily regimens. Twice-daily regimens are generally only used in specific clinical situations such as confirmed first-generation integrase inhibitor resistance.
Patients with HIV/HBV coinfection should remain on a regimen with full HBV activity. Biktarvy (FTC + TAF) is active against both. Acceptable alternatives that maintain HBV coverage include Symtuza (FTC + TAF). Regimens without dual HBV-active agents (such as DTG/3TC alone, ABC/DTG/3TC, or Juluca) are contraindicated in HBV coinfection. Abruptly stopping HBV-active therapy can cause severe hepatitis B flares.
How we reviewed this article:
Karen Cooksey researched and wrote this comparison using the DHHS Antiretroviral Guidelines, FDA prescribing information for each regimen, the pivotal clinical trials (GEMINI, TANGO, SWORD), and Medicines Patent Pool licensing data. Dr. Neha Mishra reviewed the clinical content — regimen selection, resistance, and safety — for accuracy. This page is educational and does not recommend a specific regimen; treatment decisions belong with your HIV clinician.
Read our editorial policy →Sources & References
- DHHS Panel on Antiretroviral Guidelines. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents: clinicalinfo.hiv.gov
- Cahn P et al. GEMINI-1 and GEMINI-2: Dolutegravir plus lamivudine versus dolutegravir plus tenofovir DF/emtricitabine (2019): PubMed
- Gallant J et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine. The Lancet, 2017.
- van Wyk J et al. TANGO: Switching from TDF-based triple-drug regimen to DTG/3TC: PubMed
- FDA. Biktarvy Prescribing Information (2025): accessdata.fda.gov
- FDA. Dovato Prescribing Information: accessdata.fda.gov
- Medicines Patent Pool. Licenses: medicinespatentpool.org